Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
Novo Nordisk will present 52 abstracts at the European Congress on Obesity, showcasing a portfolio that includes high-dose Wegovy and new data on women’s health during menopause.
Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Roche announces positive top-line Enspryng Phase III results from the METEOROID study, demonstrating a significant delay in relapses for patients with MOGAD.
AstraZeneca has announced that the Phase III MIRANDA trial for tozorakimab successfully met its primary endpoint, marking the third positive pivotal study for the IL-33-targeting biologic in patients with COPD.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
TECNIS PureSee IOL clinical data took center stage at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, as Johnson & Johnson [Read More…]
Johnson & Johnson MedTech has announced the European launch of its latest pulsed field ablation innovation, VARIPULSE Pro, designed to enhance procedural efficiency and precision in treating cardiac arrhythmias.
